Seen that? - FDA approves a new class of sleeping pill

Filed in archive Best of on December 8, 2009

FDA approves a new class of sleeping pill at Straightfromthedoc

A new prescription sleep aid has won FDA approval: Rozerem, the first of a new kind of sleeping pill, today gained FDA approval. Before today, many sleeping pills had potential narcotic-like effects. True, new nonbenzodiazepine sleeping pills -- such as ambien, Lunesta, and Sonata -- have greatly reduced abuse potential. But they still have a sedating effect throughout the brain. And like earlier sleep drugs, they are controlled substances under federal law. Rozerem [...] Read More


Abandoned Cancer Drug is Potential Cure for African Sleeping Sickness at Straightfromthedoc

Characterized by fever, headaches, and sleepiness, African sleeping sickness or trypanosomiasis is caused by a parasite that is transmitted to humans through the bites of tsetse fly. Previously tested in humans and animals (but now abandoned), the anticancer drug acivicin has been found to suppress the infection on mice infected with the trypanosome parasite for at least a month without serious side effects. The said parasite usually escapes destruction of its [...] Read More


Liquid Nutrition for a Peaceful Sleep at Straightfromthedoc

Welcoming winter means shorter days and longer nights, and with Daylight Savings coming up this weekend on Sunday, November 2, Americans will switch their clocks back one hour and enjoy those longer nights with one more hour of sleep. Now, AgroLabs can make that extra hour even more enjoyable with the perfect combination of ingredients to leave you well rested, refreshed, and ready to face the cooler weather. AgroLabs combining product innovation [...] Read More


MediciNova Initiates Phase II Trial on Insomnia Pill at The Biotech Weblog

Biopharmaceutical company MediciNova, Inc. announced the initiation of a Phase II clinical study to determine the safety and efficacy of MN-305 for the treatment of insomnia. MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as generalized anxiety disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed [...] Read More


Gaboxadol Shows Promise As Sleeping Pill at The Biotech Weblog

Gaboxadol shows promise as a sleeping pill for the treatment of insomnia, demonstrating in mid-stage clinical trials the ability to help patients achieve deep, or slow-wave sleep. Gaboxadol is a direct-acting Agonist of GABA-A receptor, which are believed to be involved in the regulation of sleep. Statistically significant increases in deep sleep were seen with gaboxadol at all four tested doses compared to a placebo, but the drug appeared to be [...] Read More